Editorial comment: use of recombinant human growth hormone for wasting--questions for clinical practice.
Wanke
Christine
C
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D001823:Body Composition / Q000187:drug effects; D004359:Drug Therapy, Combination; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D019247:HIV Wasting Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D011994:Recombinant Proteins; D019382:Human Growth Hormone